TABLE 4.
+Data drawn from Table S1 Himmelfarb et al. (2018) * Data drawn from Table S4 Himmelfarb et al. (2018).
| Subgroup Analysis of Phase 2 | |||||||
|---|---|---|---|---|---|---|---|
| Arm | 1 placebo | 2 Low Dose | 3 Mid Dose | 4 High Dose | 5 Highest Dose | %Diff (1-5) | |
| Subjects After Surgery | 113 | 34 | 34 | 116 | 104 | # | |
| KDIGO | 77.9 | 79.4 | 76.5 | 75.9 | 74.0 | 3.9 | % |
| p -value | 0.76 | 0.95 | 0.76 | 0.59 | |||
| sCr KDIGO | 54.9 | 58.8 | 58.8 | 56.0 | 51.9 | 3.0 | % |
| sCr>0.3 mg/dl and | 53.1 | 58.8 | 55.9 | 55.2 | 51.9 | 1.2 | % |
| Per Protocol | |||||||
| Subjects Completed + | 24 | 29 | 91 | 71 | # | ||
| KDIGO + | 78.5 | 75.0 | 75.9 | 78.0 | 70.4 | 8.1 | % |
| sCr KDIGO + | 57.0 | 54.2 | 58.6 | 56.0 | 49.3 | 7.7 | % |
| sCr >0.3mg/dl + | 55.9 | 54.2 | 55.2 | 54.9 | 49.3 | 6.6 | % |
| Per Protocol: eGFR < 60 ml/min/1.73m2 | |||||||
| Subjects Completed * | 48 | -- | -- | -- | 31 | # | |
| KDIGO * | 85.4 | -- | -- | -- | 74.2 | 11.2 | % |
| sCr KDIGO * | 75.0 | -- | -- | -- | 58.1 | 16.9 | % |
| Stage 1 AKI * | 62.5 | 35.5 | 27.0 | % | |||